Helen Nadel, MD, FRCPC, on Imperatives for Nuclear Medicine and Molecular Imaging
Dr. Nadel was announced as president of SNMMI for the 2023-2024 term at the 2023 SNMMI annual meeting taking place in Chicago.
Nuclear medicine, like many subspecialties, is facing a workforce crisis. The lack of incoming residents, techs, researchers, and other medical staff is hitting at a particularly poor time, as the role of nuclear medicine and molecular imaging is rapidly expanding with newfound applications in oncology, neurodegenerative disorders, and beyond.
The lack of staffing is top of mind for the Society of Nuclear Medicine and Molecular Imaging's incoming president Helen Nadel, MD, FRCPC, who began her year-long term at this year's SNMMI Annual Meeting, taking place June 24-27, 2023 in Chicago.
Dr. Nadel, who is director of pediatric nuclear medicine at Lucile Packard Children’s Hospital at Stanford and clinical professor of radiology at the Stanford School of Medicine, told Diagnostic Imaging that recruitment efforts are in full effect, with targeted programs being rolled out that focus on early education opportunities. For instance, the society held an information fair for interested high school students during the annual meeting, where children and their parents were welcome to tour exhibits and learn more about the specialty.
Dr. Nadel and other SNMMI leadership are also focused on boosting the profile of nuclear medicine, molecular imaging, and theranostics globally by partnering with other organizations and associations in the space to produce best practice guidelines and appropriate use critieria.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
